

Total No. of Questions : 11]

SEAT No. :

P1132

[4659]-358

[Total No. of Pages : 2

B.E.(Biotechnology)

C-BIO-THERAPEUTICS TECHNOLOGY (415461)

(Elective I) (2008 Pattern)(Semester-I)

Time : 3 Hours]

[Max. Marks : 100

Instructions to the candidates:

- 1) *Answers to the two sections should be written in separate answer-books.*
- 2) *Answer Q1 or 2, Q3 or 4, Q5 or 6 from section I and Q7 or 8, Q9 and Q10 or Q11 from section II.*
- 3) *Neat diagrams must be drawn wherever necessary.*
- 4) *Figures to the right side indicate full marks.*
- 5) *Use of Calculator is allowed.*
- 6) *Assume Suitable data if necessary.*

SECTION-I

Q1) Giving examples give an account of biotherapeutics products. **[18]**

OR

Q2) Give comparative account of traditional drugs and Biopharmaceuticals. **[18]**

Q3) a) Giving examples explain how the insect cell lines are used for production of biotherapeutics. **[8]**

b) Enlist 5 recombinant proteins and briefly write on the applications and host used for production. **[8]**

OR

Q4) a) With the help of flow chart give outline of hybridoma technique for production of MAb. **[8]**

b) Describe ADME of monoclonal antibody given by parenteral route. **[8]**

Q5) Describe in detail advantages and disadvantages of various sources of Biotherapeutic proteins. **[16]**

OR

P.T.O.

Q6) What are the methods of production of recombinant biotherapeutic proteins using plants and animals. [16]

SECTION-II

Q7) Describe the process of decontamination, sanitation and Generation of water for biopharmaceutical manufacturing. [18]

OR

Q8) Give an overview of range and significance of biopharmaceutical product impurities like microorganisms, viruses, contaminant proteins, DNA and pyrogens. [18]

Q9) Write short notes on any two- [16]

- a) QC of final biopharmaceutical product,
- b) Stability of biopharmaceuticals,
- c) Biopharmaceutical validation,
- d) Nano drug delivery.

Q10) Give an account of various types of clinical trials and role of DCGI. [16]

OR

Q11) Write notes on any TWO: [16]

- a) IPR and Patents,
- b) GMP,
- c) Toxicity studies,
- d) Pre-clinical studies.

□□□